Translate Bio (Translate Bio) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Cyclically Adjusted Price-to-FCF?

Translate Bio does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

Translate Bio Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Translate Bio's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Cyclically Adjusted Price-to-FCF Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Cyclically Adjusted Price-to-FCF

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cyclically Adjusted Price-to-FCF	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Translate Bio's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Translate Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Translate Bio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Translate Bio's Cyclically Adjusted Price-to-FCF falls into.

Translate Bio Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Translate Bio does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Translate Bio (NAS:TBIO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.

Translate Bio Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Translate Bio's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Cyclically Adjusted Price-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109